Does tocilizumab have an effect on the clinical outcomes in COVID-19 patients? A meta-analysis of randomized control trials.

Faezeh GhaempanahMaziar NikoueiMojtaba CheraghiArman JahangiriYousef Moradi

Published in: Journal of pharmaceutical policy and practice (2023)

The administration of tocilizumab during the COVID-19 pandemic, prescribed to patients with the virus, exerted a noteworthy impact on reducing outcomes associated with COVID-19.

Keyphrases

sars cov
rheumatoid arthritis
juvenile idiopathic arthritis
rheumatoid arthritis patients
coronavirus disease
double blind
open label
disease activity
phase ii
respiratory syndrome coronavirus
clinical trial
systemic lupus erythematosus
skeletal muscle
study protocol